Eli Lilly Stock Soars, Boosted by Weight-Loss Pill Trial Results; Rival Novo Nordisk Slumps
Eli Lilly Stock Soars, Boosted by Weight-Loss Pill Trial Results; Rival Novo Nordisk Slumps
By Mackenzie Tatananni and George Glover
作者:麥肯齊·塔塔南尼和喬治·格洛弗
$Eli Lilly and Co (LLY.US)$ stock soared Thursday after the pharmaceutical giant said its new weight-loss pill had cleared a late-stage clinical trial, bringing Lilly one step closer to snapping up market share from rival $Novo-Nordisk A/S (NVO.US)$.
$禮來 (LLY.US)$ 在製藥巨頭宣佈新款減肥藥通過晚期臨牀試驗後,股票在星期四大幅上漲,這使得禮來更接近於從競爭對手那裏搶佔市場份額。 $諾和諾德 (NVO.US)$.
Lilly said in a news release that its orforglipron pill had passed a Stage 3 trial with "statistically significant efficacy results" and a safety profile consistent with injectable obesity drugs that already are on the market.
莉莉在一份資訊發佈中表示,其orforglipron藥丸已通過三期試驗,顯示出"統計學上顯著的療效結果",且安全性與市場上已有的注射性肥胖藥物一致。
Orforglipron is a GLP-1 receptor agonist that works similarly to medications like Novo's Ozempic. The pill mimics the effects of the hormone glucagon-like peptide-1, which plays a role in regulating appetite and blood sugar levels.
Orforglipron是一種GLP-1受體激動劑,作用類似於Novo的Ozempic等藥物。這種藥丸模擬了胰高血糖素樣肽-1激素的作用,該激素在調節食慾和血糖水平中起着重要作用。
Data collected during the trial showed that orforglipron was as safe to use as injectable GLP-1 medicines currently on the market. Patients on the highest dose lost an average of 16 pounds, or 7.9% of their weight, after 40 weeks.
試驗收集的數據表明,orforglipron的安全性與目前市場上的注射GLP-1藥物相當。最高劑量的患者在40周後平均減重16磅,約佔其體重的7.9%。
However, it did lag behind competitors in one area. The pill helped lower hemoglobin A1c by an average of 1.3% to 1.6% from a starting level of 8% across different doses. Patients who took a placebo saw a 0.1% reduction in blood sugar levels. By comparison, hemoglobin A1c was lowered by closer to 2% in people who took Novo's Ozempic.
然而,在某些方面,它在競爭中落後。這種藥丸平均降低了血紅蛋白A1c的水平,減少幅度爲1.3%至1.6%,起始水平爲8%。服用安慰劑的患者血糖水平僅下降了0.1%。相比之下,服用Novo的Ozempic的人血紅蛋白A1c下降接近2%。
But it seems investors weren't concerned by the nuances, as evidenced by the stock price. Eli Lilly shares surged 16% to $852.76 on Thursday while the benchmark S&P 500 rose 0.3%. The stock was on pace for the largest daily percentage increase since June 29, 2000, when it rose nearly 18%, according to Dow Jones Market Data.
但投資者似乎並沒有被這些細微差別所困擾,股價就是明證。週四,埃利·莉莉的股票上漲了16%,達到852.76美元,而基準S&P 500指數上漲了0.3%。根據道瓊斯市場數據,這隻股票正朝着自2000年6月29日以來最大的每日百分比漲幅邁進,那時其漲幅接近18%。
As Lilly rose, U.S.-listed shares of Novo Nordisk, the maker of Ozempic and its most formidable rival in the weight-loss market, declined 7.3%.
隨着莉莉股價上升,美國上市的Novo Nordisk,即Ozempic的製造商及其在減肥市場上最強大的競爭對手,股價下跌了7.3%。
Orforglipron is more than just a tool for weight management, it's intended for use in diabetes patients as well. Lilly stressed that approval of the drug would advance the company's mission "to reduce chronic diseases like type 2 diabetes."
奧福格列隆不僅僅是一個體重管理的工具,它還計劃用於糖尿病患者。禮來公司強調,藥物的批准將推動公司減少"像2型糖尿病這樣的慢性疾病"的使命。
As an oral treatment, the pill differs by design from the GLP-1 injectables that currently saturate the market. In theory, orforglipron would be easier to manufacture and produce than an injectable medicine, giving Lilly an edge over competitors like Novo.
作爲一種口服治療,這種藥丸在設計上不同於目前市場上充斥的GLP-1注射劑。從理論上講,奧福格列隆的製造和生產要比注射藥物更容易,這使禮來在競爭對手諾和諾德面前處於優勢。
"As a convenient once-daily pill, orforglipron may provide a new option and, if approved, could be readily manufactured and launched at scale for use by people around the world," Lilly CEO David Ricks said in the release.
禮來首席執行官大衛·裏克斯在發佈中表示:"作爲一種方便的每日一片的藥丸,奧福格列隆可能提供一個新的選擇,並且如果獲批,可以大規模製造和推出,供世界各地的人們使用。"
Orforglipron is not the first oral GLP-1 receptor agonist -- the differences are more nuanced than that. Novo's Rybelsus, a peptide-based oral semaglutide, was approved by the Food and Drug Administration back in 2019. The FDA approved a label update for Rybelsus in 2023, allowing it to be used as an initial therapy for adults with type 2 diabetes.
奧福格列隆並不是首個口服GLP-1受體激動劑——它們之間的差別更爲細微。諾和諾德的Rybelsus,一種基於肽的口服賽馬魯肽,於2019年獲得食品和藥物管理局批准。FDA在2023年批准了Rybelsus的標籤更新,允許其作爲2型糖尿病成年患者的初始治療。
Beyond the differences in chemical composition, Rybelsus must be taken with food, while this is optional for people taking orforglipron.
除了化學成分的區別外,Rybelsus必須與食物一起服用,而服用奧福格列隆的人則可以選擇不與食物同服。
Competition in the market is stiff, and Lilly aims to set itself apart. Its treatment portfolio spans a range of medical specialties from oncology to immunology. Following the success of Zepbound and Mounjaro, the company is particularly eager to expand its basket of weight-loss drugs.
市場競爭非常激烈,禮來公司旨在使自己脫穎而出。其治療組合涵蓋了從腫瘤學到免疫學的各種醫療專業。繼Zepbound和Mounjaro的成功之後,公司尤其渴望擴展其減肥藥物組合。
Zepbound and Mounjaro certainly have earned their reputation as blockbuster drugs. Lilly noted that their volume growth was the driver behind a 45% increase in revenue during the most recent quarter.
Zepbound和Mounjaro無疑已經贏得了其作爲暢銷藥物的聲譽。禮來指出,它們的成交量增長推動了最近一個季度營業收入的45%的增長。
If orforglipron passes every trial and ultimately secures FDA approval, Lilly is confident it will be able "to launch the drug worldwide without supply constraints," the company said.
如果奧福格列隆通過每項試驗並最終獲得FDA批准,禮來公司有信心能夠"在沒有供應限制的情況下在全球推出該藥物,"公司表示。
Orforglipron is roughly halfway through its seven scheduled Phase 3 trials. Assuming all goes according to plan, Lilly said it expects to file for regulatory approval of the pill for obesity by the end of the year, and for diabetes in 2026.
Orforglipron大約完成了其七個計劃中的第三階段臨牀試驗的中間階段。根據計劃,Lilly表示預計將在年底之前向監管機構申請該藥物用於肥胖症的批准,而對於糖尿病則在2026年。
Write to Mackenzie Tatananni at mackenzie.tatananni@barrons.com and George Glover at george.glover@dowjones.com
請寫信給Mackenzie Tatananni,郵箱是mackenzie.tatananni@barrons.com,以及George Glover,郵箱是george.glover@dowjones.com
This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.
這內容是由Barron's創建的,Barron's由道瓊斯公司運營。Barron's與道瓊斯新聞社和華爾街日報獨立出版。